373 related articles for article (PubMed ID: 32754615)
1. Dynamics of Cellular Plasticity in Prostate Cancer Progression.
Tiwari R; Manzar N; Ateeq B
Front Mol Biosci; 2020; 7():130. PubMed ID: 32754615
[TBL] [Abstract][Full Text] [Related]
2. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
Cheng WC; Wang HJ
Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression.
Kaarijärvi R; Kaljunen H; Ketola K
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572108
[TBL] [Abstract][Full Text] [Related]
4. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
5. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
Dicken H; Hensley PJ; Kyprianou N
Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer.
Nanda JS; Koganti P; Perri G; Ellis L
Crit Rev Oncog; 2022; 27(1):45-60. PubMed ID: 35993978
[TBL] [Abstract][Full Text] [Related]
8. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
[TBL] [Abstract][Full Text] [Related]
9. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
[TBL] [Abstract][Full Text] [Related]
11. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
12. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
Sreekumar A; Saini S
Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
[TBL] [Abstract][Full Text] [Related]
13. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
Altschuler J; Stockert JA; Kyprianou N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
[TBL] [Abstract][Full Text] [Related]
14. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.
Patel GK; Chugh N; Tripathi M
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547070
[TBL] [Abstract][Full Text] [Related]
16. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Davies AH; Beltran H; Zoubeidi A
Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
[TBL] [Abstract][Full Text] [Related]
17. Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer.
Sreekumar A; Saini S
Front Cell Dev Biol; 2023; 11():1075707. PubMed ID: 36711033
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer.
Ravindran Menon D; Hammerlindl H; Torrano J; Schaider H; Fujita M
Theranostics; 2020; 10(14):6261-6277. PubMed ID: 32483452
[TBL] [Abstract][Full Text] [Related]
19. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
20. Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.
Jindal R; Nanda A; Pillai M; Ware KE; Singh D; Sehgal M; Armstrong AJ; Somarelli JA; Jolly MK
Comput Struct Biotechnol J; 2023; 21():1498-1509. PubMed ID: 36851919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
